News

A never-before-reported mutation in the CD46 gene was found to contribute to the development of atypical hemolytic uremic syndrome (aHUS) in a young man in China, a study reports. According to researchers, “this finding broadens the spectrum of CD46 gene variants associated with aHUS, providing a critical basis for clinical diagnosis, genetic…

Two infections — influenza followed by COVID-19 — were trigger events for separate episodes of atypical hemolytic uremic syndrome (aHUS) in a young man in Japan, a case study reports. The researchers noted that the man’s “[two] episodes of recurrent aHUS following respiratory tract infections” resolved without the need…

Pericardial effusion — a potentially life-threatening disorder marked by the buildup of fluid around the heart — can affect people with atypical hemolytic uremic syndrome (aHUS), though it may not cause obvious symptoms, and aHUS patients should be screened for it, scientists said. The scientists, after reading a…

For this year’s aHUS Awareness Day — held annually on Sept. 24 — advocates worldwide will focus on managing the rare disease, asking people with atypical hemolytic uremic syndrome (aHUS) to share the single best decision they’ve made regarding their care. “Atypical hemolytic uremic syndrome impacts every aspect of…

People with atypical hemolytic uremic syndrome (aHUS) who’ve had a kidney transplant can safely switch from Soliris (eculizumab) to Ultomiris (ravulizumab-cwvz) without risking a recurrence of the disease. That’s according to a real-world study that also found that blood and kidney-related disease markers remained stable after the switch, and…

People with atypical hemolytic uremic syndrome (aHUS) who stop taking Soliris (eculizumab) have a 16.5% higher risk of having a relapse, while those who continue treatment have a 76% lower relapse risk, a meta-analysis of published studies suggests. The differences, however, were only seen in case-control studies, not…

Adults with atypical hemolytic uremic syndrome (aHUS) in the U.K. who didn’t receive treatment with Soliris (eculizumab) had a 43% chance of developing end-stage kidney disease within five years, according to a study that found this severe form of kidney damage was less likely in children within the…

Soliris (eculizumab) helped ease disease symptoms for a woman with multiple myeloma who developed atypical hemolytic uremic syndrome (aHUS) as a complication of a viral infection caused by H1N1 influenza — also known as influenza A, or swine flu. “The prompt recognition and initiation of anti-complement therapy played…

Most people with atypical hemolytic uremic syndrome (aHUS) who are stable on Soliris (eculizumab) can stop treatment after at least six months without having a relapse, provided that they’re carefully monitored, a recent study reported. Scientists expect that this could prevent treatment-related complications and burden for patients, while…

Atypical hemolytic uremic syndrome (aHUS) can occur as a rare complication of surgery involving the urinary tract, according to a report from Italy detailing the case of a woman in her 40s who developed the condition after undergoing a procedure to remove kidney stones. The patient, who had a…